Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EWTX Edgewise Therapeutics	$14.93 +1.6%	$14.74	$10.60 ▼ $38.12	$1.57B	0.36	1.18 million shs	510,056 shs
TGTX TG Therapeutics	$36.71 +2.7%	$37.30	$15.16 ▼ $46.48	$5.83B	2.21	2.96 million shs	804,312 shs
TLX Telix Pharmaceuticals Limited American Depositary Shares	$16.98 +1.0%	$16.75	$13.61 ▼ $30.36	$5.74B	N/A	26,338 shs	15,727 shs
VRNA Verona Pharma	$84.66 +0.7%	$65.98	$11.75 ▼ $85.17	$6.86B	0.2	1.32 million shs	1.08 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EWTX Edgewise Therapeutics	+3.45%	+3.38%	-13.13%	-40.04%	-14.24%
TGTX TG Therapeutics	+1.22%	+3.41%	-17.70%	+0.36%	+119.33%
TLX Telix Pharmaceuticals Limited American Depositary Shares	+0.27%	+1.20%	-10.16%	-4.05%	+1,679,999,900.00%
VRNA Verona Pharma	+4.05%	+12.04%	+15.63%	+24.59%	+596.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EWTX Edgewise Therapeutics	3.303 of 5 stars	4.4	2.0	0.0	0.0	3.1	3.3	0.0
TGTX TG Therapeutics	3.7788 of 5 stars	2.4	2.0	0.0	3.5	2.9	1.7	1.9
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma	1.5278 of 5 stars	2.6	1.0	0.0	0.0	2.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EWTX Edgewise Therapeutics	2.78	Moderate Buy	$40.22	169.41% Upside
TGTX TG Therapeutics	2.80	Moderate Buy	$40.80	11.14% Upside
TLX Telix Pharmaceuticals Limited American Depositary Shares	3.00	Buy	$22.00	29.56% Upside
VRNA Verona Pharma	3.11	Buy	$82.13	-2.99% Downside

Current Analyst Ratings Breakdown

Latest EWTX, VRNA, TLX, and TGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	VRNA Verona Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$85.00 ➝ $90.00
4/30/2025	EWTX Edgewise Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$41.00
4/30/2025	VRNA Verona Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$93.00 ➝ $107.00
4/30/2025	VRNA Verona Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$75.00 ➝ $85.00
4/28/2025	VRNA Verona Pharma	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
4/28/2025	VRNA Verona Pharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$100.00
4/21/2025	EWTX Edgewise Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$43.00 ➝ $43.00
4/21/2025	VRNA Verona Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$80.00
4/3/2025	EWTX Edgewise Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$56.00 ➝ $52.00
4/2/2025	EWTX Edgewise Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$51.00 ➝ $51.00
4/2/2025	EWTX Edgewise Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$50.00 ➝ $14.00

(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.53 per share	N/A
TGTX TG Therapeutics	$386.39M	15.08	$0.10 per share	353.90	$1.06 per share	34.63
TLX Telix Pharmaceuticals Limited American Depositary Shares	$783.21M	7.33	N/A	N/A	N/A	∞
VRNA Verona Pharma	$118.54M	57.91	N/A	N/A	$3.10 per share	27.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EWTX Edgewise Therapeutics	-$100.16M	-$1.55	N/A	N/A	N/A	N/A	-26.83%	-25.67%	8/7/2025 (Estimated)
TGTX TG Therapeutics	$12.67M	$0.24	N/A	36.71	N/A	-5.42%	-8.32%	-3.40%	8/5/2025 (Estimated)
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	0.00	35.38	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma	-$54.37M	-$2.00	N/A	2,822.00	N/A	N/A	-79.54%	-43.49%	8/14/2025 (Estimated)

Latest EWTX, VRNA, TLX, and TGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	EWTX Edgewise Therapeutics	-$0.45	-$0.43	+$0.02	-$0.43	N/A	N/A
5/7/2025	Q1 2025	TGTX TG Therapeutics	$0.19	$0.03	-$0.16	$0.03	$117.07 million	$120.86 million
4/29/2025	Q1 2025	VRNA Verona Pharma	-$0.22	$0.27	+$0.49	-$0.16	$41.47 million	$98.65 million
3/3/2025	Q4 2024	EWTX Edgewise Therapeutics	-$0.39	-$0.42	-$0.03	-$0.42	N/A	N/A
3/3/2025	Q4 2024	TGTX TG Therapeutics	$0.08	$0.15	+$0.07	$0.15	$100.67 million	$108.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EWTX Edgewise Therapeutics	N/A	26.35	26.35
TGTX TG Therapeutics	1.27	4.59	3.91
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A
VRNA Verona Pharma	0.93	13.03	12.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EWTX Edgewise Therapeutics	N/A
TGTX TG Therapeutics	58.58%
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A
VRNA Verona Pharma	85.88%

Insider Ownership

Company	Insider Ownership
EWTX Edgewise Therapeutics	23.20%
TGTX TG Therapeutics	10.64%
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A
VRNA Verona Pharma	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EWTX Edgewise Therapeutics	60	105.20 million	71.86 million	Optionable
TGTX TG Therapeutics	290	158.76 million	139.32 million	Optionable
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	337.97 million	N/A	N/A
VRNA Verona Pharma	30	81.08 million	76.10 million	Optionable

EWTX, VRNA, TLX, and TGTX Headlines

Recent News About These Companies

Hennion & Walsh Asset Management Inc. Purchases 5,766 Shares of Verona Pharma plc (NASDAQ:VRNA)

June 3 at 7:46 AM | marketbeat.com

Hamilton Lane Advisors LLC Takes $1.65 Million Position in Verona Pharma plc (NASDAQ:VRNA)

June 3 at 6:44 AM | marketbeat.com

HC Wainwright Forecasts Strong Price Appreciation for Verona Pharma (NASDAQ:VRNA) Stock

June 3 at 2:09 AM | americanbankingnews.com

Verona Pharma (NASDAQ:VRNA) Reaches New 12-Month High Following Analyst Upgrade

June 3 at 1:15 AM | americanbankingnews.com

Verona Pharma (NASDAQ:VRNA) Hits New 1-Year High After Analyst Upgrade

June 2 at 10:35 AM | marketbeat.com

Verona Pharma (NASDAQ:VRNA) Price Target Raised to $90.00 at HC Wainwright

June 2 at 8:17 AM | marketbeat.com

Two Sigma Advisers LP Buys New Shares in Verona Pharma plc (NASDAQ:VRNA)

June 2 at 4:07 AM | marketbeat.com

7,800 Shares in Verona Pharma plc (NASDAQ:VRNA) Acquired by Northern Trust Corp

June 2 at 3:14 AM | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) Shares Sold by Bank of America Corp DE

June 1 at 3:28 AM | marketbeat.com

Verona Pharma (NASDAQ:VRNA) Shares Gap Up - What's Next?

June 1 at 2:45 AM | americanbankingnews.com

Verona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 32,432 Shares

May 31 at 5:45 PM | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) CEO Sells $320,208.00 in Stock

May 31 at 5:45 PM | marketbeat.com

David Zaccardelli Sells 157,704 Shares of Verona Pharma plc (NASDAQ:VRNA) Stock

May 31 at 5:29 PM | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 162,704 Shares

May 31 at 5:29 PM | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 204,864 Shares

May 31 at 5:29 PM | marketbeat.com

David Zaccardelli Sells 208,696 Shares of Verona Pharma plc (NASDAQ:VRNA) Stock

May 31 at 5:29 PM | marketbeat.com

Verona Pharma (NASDAQ:VRNA) Shares Gap Up - Time to Buy?

May 31 at 11:42 AM | marketbeat.com

10,310 Shares in Verona Pharma plc (NASDAQ:VRNA) Bought by NorthCrest Asset Manangement LLC

May 31 at 4:52 AM | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) CFO Sells $309,076.96 in Stock

May 30, 2025 | insidertrades.com

Jim Cramer Notes Verona Pharma plc (VRNA) “Loses a Lot of Money”

May 29, 2025 | insidermonkey.com

Verona Pharma (NASDAQ:VRNA) Sets New 52-Week High - Still a Buy?

May 28, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EWTX, VRNA, TLX, and TGTX Company Descriptions

Edgewise Therapeutics NASDAQ:EWTX

$14.93 +0.24 (+1.63%)

As of 02:14 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

TG Therapeutics NASDAQ:TGTX

$36.71 +0.96 (+2.69%)

As of 02:17 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Telix Pharmaceuticals Limited American Depositary Shares NASDAQ:TLX

$16.98 +0.17 (+1.01%)

As of 02:16 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Verona Pharma NASDAQ:VRNA

$84.66 +0.56 (+0.67%)

As of 02:15 PM Eastern

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time